CD4 and thymus lymphoma: As expected HSCT combined with a clinically relevant non-myeloablative host-conditioning regimen inhibited development of thymic lymphomas prolonging the lifespan of Atm-deficient mice through the restoration of the CD4 as well as the CD8 T-lymphocyte populations over time (24).